With oral dosing of edoxaban , co-administration of various P-gp inhibitors significantly increased edoxaban bioavailability and decreased volume of distribution ( V 2 ) , resulting in a predicted increase of 33-77 % in area under the curve ( AUC ) and 65-104 % in C max .